ImmunogenicityMarch 2026
Zero Off-Target: Achieving 100% Human Framework Identity in de novo VHH
Anti-drug antibodies (ADA) remain the leading cause of biologic failure in late-stage clinical trials. New humanization strategies using germline framework grafting are dramatically reducing immunogenicity risk for camelid-derived nanobodies.
JFInnova Perspective
JFIN-0001 was designed with 100% framework identity to the human IGHV3-11 germline, achieving Grade A humanization (T20 score 78.9%) — effectively indistinguishable from a human antibody by the immune system.
References
1
The Therapeutic Potential of Nanobodies
BioDrugs · 2020
Humanized nanobody immunogenicity